Titlebook: Drug Development in Psychiatry; Matthew Macaluso,Sheldon H. Preskorn,Richard C. Sh Book 2023 The Editor(s) (if applicable) and The Author(

嫻熟

外來

Post-Approval Research in Drug Development: Priorities and Practices,hic and comorbid clinical characteristics. Is this medicine more effective, safe, tolerable, or affordable than the options used in the past? A payer may ask if the new medication offers a more effective, cost-efficient, or convenient alternative to those treatments already being covered. These are

貨物

Folklore

Targeted Treatments for Fragile X Syndrome,neurobiology of FXS have identified a number of pathways that are dysregulated in the absence of FMRP and are therefore pathways that can be targeted with new medication. The utilization of quantitative outcome measures to assess efficacy in multiple studies has improved the quality of more recent t

小鹿

The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders,tments with the potential to have a significant impact on human health. CNS diseases, however, present particular challenges to therapeutic discovery efforts, and psychiatric diseases/disorders may be among the most difficult. With specific exceptions such as psychostimulants for ADHD, a large numbe

易于出錯

indemnify

毛細(xì)血管

Mercurial